Literature DB >> 2684602

Extracranial skull base chondrosarcoma.

M D Seidman, R D Nichols, U B Raju, B Mehta, H G Levy.   

Abstract

Chondrosarcoma of the skull base is a rare neoplasm. The most common presenting symptoms are hoarseness, dysphagia, and diplopia, which is associated with palsies of cranial nerves X, IX, and VI. The temporal bone is the most common site of tumor origin, followed by the sphenoid bone. These tumors must be differentiated from chordoma, chondroid chordoma, osteogenic sarcoma, enchondroma, and meningioma. Diagnosis is made by patient history, radiologic imaging, and biopsy. The treatment is surgical excision followed by radiation therapy. Five-year survival rates for grades I, II, and III are 90, 81, and 43%, respectively.

Entities:  

Mesh:

Year:  1989        PMID: 2684602

Source DB:  PubMed          Journal:  Ear Nose Throat J        ISSN: 0145-5613            Impact factor:   1.697


  4 in total

1.  Cranial chondrosarcoma and recurrence.

Authors:  Orin G Bloch; Brian J Jian; Isaac Yang; Seunggu J Han; Derick Aranda; Brian J Ahn; Andrew T Parsa
Journal:  Skull Base       Date:  2010-05

Review 2.  A systematic review of proton therapy in the treatment of chondrosarcoma of the skull base.

Authors:  Maurizio Amichetti; Dante Amelio; Marco Cianchetti; Riccardo Maurizi Enrici; Giuseppe Minniti
Journal:  Neurosurg Rev       Date:  2010-04       Impact factor: 3.042

Review 3.  A systematic review of intracranial chondrosarcoma and survival.

Authors:  Orin G Bloch; Brian J Jian; Isaac Yang; Seunggu J Han; Derick Aranda; Brian J Ahn; Andrew T Parsa
Journal:  J Clin Neurosci       Date:  2009-09-30       Impact factor: 1.961

4.  Successful chemoradiation therapy for high-grade skull base chondrosarcoma in a child.

Authors:  T Yoshimoto; Y Sawamura; J Ikeda; N Ishii; H Abe
Journal:  Childs Nerv Syst       Date:  1995-04       Impact factor: 1.475

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.